Benefits
Sustained energy without spike-and-crash
The Extended Release form releases caffeine gradually (≤55% at 1 hour, ≥80% by 6 hours), flattening the plasma peak that drives jitters and the subsequent crash with immediate-release caffeine. Plasma caffeine rises and falls over hours rather than spiking in 30-60 minutes. Total caffeine exposure is the same — only the timing differs.
Delayed-surge profile for timed performance
The Delayed Release form holds caffeine in a bioadhesive polymer for ~90 minutes, then releases ≥80% within an hour. Useful when an athlete or worker wants the caffeine peak to land at a specific later time rather than immediately after dosing.
Liquid-stable form for energy shots and beverages
The Liquid-Stable form (launched 2017 at IFT17) adapts the ER technology to 2-4 oz beverage applications. Microspheres remain dispersed in the liquid rather than floating, with gradual 5-6 hour release. Targets the energy shot market where conventional ER caffeine doesn't survive a liquid matrix.
Custom energy curves via IR + ER + DR blending
Formulators can combine immediate-release, extended-release, and delayed-release caffeine in a single product to design specific energy curves — a fast onset from IR, sustained tail from ER, or a delayed second wave from DR. PLT publishes pharmacokinetic models for hypothetical blends to support formulation.
Heat-stable, pH-independent release
The ER and LS lipid coating is non-pH-dependent (release is enzymatic rather than triggered by stomach vs intestinal pH) and heat-stable, which allows use in beverages, gummies, bars, and gels — applications where conventional wax-based caffeine coatings fail. Manufactured under USP dissolution methodology with batch-level release-profile verification.
Mechanism of action
Caffeine pharmacology is unchanged
zümXR® alters caffeine's dissolution and absorption — not its metabolism or receptor binding. Once absorbed, the caffeine acts identically to immediate-release caffeine: adenosine A1/A2A receptor antagonism (promoting wakefulness and alertness) and catecholamine release (supporting ergogenic and thermogenic effects). Same molecule, same half-life once absorbed — the difference is the rate it enters circulation.
Non-pH-dependent lipid coating (ER + LS)
Extended Release and Liquid-Stable forms use a lipid-based coating that releases caffeine via enzymatic processes in the GI tract rather than pH-triggered dissolution. This makes the release profile consistent across stomach and small-intestine pH, and heat-stable enough for hot-process applications.
Bioadhesive polymer (DR)
The Delayed Release form uses a bioadhesive polymer that holds the caffeine bead intact for approximately 90 minutes before releasing the payload rapidly. The result is a delayed-onset surge rather than a sustained release.
Encapsulated micro-bead architecture
zümXR uses micro-bead encapsulation with controlled payload delivery rather than a monolithic coating on a tablet. This allows the ingredient to be incorporated into powders, gummies, bars, beverages, and stick packs — formats that monolithic tablet coatings cannot serve.
Clinical trials
Two-arm crossover comparing 400 mg zümXR Extended-Release vs 400 mg immediate-release anhydrous caffeine in habitual moderate caffeine consumers (200-400 mg/day) following partial sleep deprivation (<5 hours). Measurements at 45, 60, 90, 135, 240, 300, 360, and 420 minutes post-dose. Validates the ER specification of ≤55% release at 1 hour and ≥80% at 6 hours and the resulting flattened plasma peak.
Earlier PK study comparing zümXR-ER to immediate-release anhydrous caffeine reported a substantially extended caffeine half-life for the zümXR formulation. Underpins the commercial release specifications. Note: industry-funded; results are PK validation rather than efficacy outcomes.
Third-party consumer survey of 161 men ages 20-40 regularly using pre-workout products. Participants reported they would be 2.5× more likely to choose a targeted-release caffeine pre-workout vs their current product. Note: this is a market-preference survey, not a clinical efficacy trial.